Deep Vein ThrombosisThrombUS_ANCT06989255
A Multi-center Cohort Study for Conventional Ultrasound Image Set Collection to Create a Data Set for Research Purposes.
An observational study of Deep Vein Thrombosis, run by ThrombUS+ at 5 sites in 4 countries.
Trial summary
This study aims to collect and create a labelled ultrasound image data set containing ultrasound image series and video clips of patients that undergo routine ultrasound scans on lower limbs, because of suspected deep vein thrombosis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Deep Vein Thrombosis
- How many people
- 3,000 participants
- Where
- 5 sitesin 4 countries
- Study dates
- 6 Nov 2024to 31 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with suspected DVT referred for a DVT ultrasound scan will be consecutively selected to account for demographics, medical condition and ultrasound operator diversity in the sample; data selected will be anonymized and included in the data set. In and out-patients referred for an ultrasound scan for suspected DVT will be asked to participate (informed consent process).
Who may be able to join
- Age ≥18 years.
- The participant has the capacity to consent, and consent is obtained prior to any study-specific procedures.
- The conventional diagnostic DVT algorithm indicates that an ultrasound is needed, or the patient has been referred for a scan on suspicion of DVT.
Who cannot join
- Patients with a known condition or reason that may potentially result in interrupting or stopping the ultrasound examination before its completion.
- Patients considered by their treating physician or the ultrasound operator as non-suitable for a standard ultrasound scan.
- Patients who have not signed the informed consent.
Trial locations and contacts
5 sites in 4 countries. Contact the study team or a site near you to ask about taking part.
5 sites in 4 countries
Greece2 sites, 2 recruiting
- Recruiting
University General Hospital of Alexandroupoli
Alexandroupoli, GR 68100
Savvas Defteraios, Prof., +30 6948054408, sdefter@med.duth.gr
Savvas Defteraios, Prof.
- Recruiting
Papageorgiou General Hospital
Thessaloniki, 54603
Maria Bigaki, Mrs, +30 6932478047, pmo@papageorgiou-hospital.gr
Michail Potoupnis, Prof.
France1 site, 1 recruiting
- Recruiting
Groupement Hospitalier Eaubonne Montmorency Simone Veil
Montmorency, 95160
Maxime Gautier, +33 134066763, maxime.gautier@ch-simoneveil.fr
Maxime Gautier, Dr.
Italy1 site, 1 recruiting
- Recruiting
Home Relief of Suffering Hospital
San Giovanni Rotondo, FG 71013
Elvira Grandone, Prof., +39 0882416286, e.grandone@operapadrepio.it
Elvira Grandone, Prof.
Lithuania1 site, 1 recruiting
- Recruiting
Lithuanian University of Health Science
Kaunas, 44307
Andrius Macas, Prof., + 37 037327305, andrius.macas@lsmu.lt
Andrius Macas, Prof.
About this study
Official title: A Multi-center Cohort Study for Conventional Ultrasound Image Set Collection to Create a Training Data Set for Research Purposes (Image Processing and Analysis, AI Model Training).
This study aims to collect and create a labelled ultrasound image data set containing ultrasound image series and video clips of patients that undergo routine ultrasound scans on lower limbs, because of suspected deep vein thrombosis.
The data will be used to train an AI model within ThrombUS+ project to achieve automated detection of deep vein thrombosis on conventional ultrasound scans.
Read more
Primary objectives:
- Collect and curate imaging data from ultrasound scans of patients suspected for DVT.
- Collect accompanying metadata on patient demographics, referral note, existing known medical conditions at the time of scan, diagnosis based on the scan, operator anonymized ID, metadata on the ultrasound equipment used.
- Anonymize the data set according to established regulations to be used for research purposes and in specific for training an artificial intelligence model to achieve automated DVT detection.
Secondary objectives:
- Describe the data set in the Argos/OpenAIRE tool and make it publicly available through the European Open Science Cloud (EOSC) portal via OpenAIRE, to be used by other researchers for image processing, analysis, and artificial intelligence (AI) model training.
Read the detailed description
Deep vein thrombosis (DVT) and its fatal complication pulmonary embolism (PE) afflict millions of people worldwide and are responsible for a large percentage of acute hospitalizations. Clinical assessment of DVT is notoriously unreliable because up to 2/3 of DVT episodes are clinically silent and patients are symptom free even when PE has developed. Symptomatic DVT events, that are eventually referred for ultrasound imaging are only the tip of the DVT iceberg. The subgroup of events that evolve to develop clinical indications cannot be accurately predicted and often lead to sudden death from PE regarded as "the leading cause of preventable death in hospitalized patients" and "the number one priority for improving patient safety in hospitals".
Deep vein thrombosis (DVT) is the formation of a blood clot within the deep veins, most commonly those of the lower limbs, causing obstruction of blood flow. In 50% of people with DVT, the clot is at some point detached from the vein wall and travels to the lung to cause pulmonary embolism. About 25% of people experiencing pulmonary embolism (PE) will die from it, making it the 3rd leading cause of cardiovascular death worldwide after stroke and heart attack. Even in patients who do not get PE, recurrent thrombosis and "post-thrombotic syndrome" are major causes of mortality and reduced quality of life.
Recent European population studies report DVT incidence of 70-140 cases/100,000 person-year, which translates to roughly 522,000 to 1.04 million cases per year in Europe. Respectively, Center for Disease Control and Prevention (CDC) reports around 900,000 DVT incidents per year in USA, with an estimate of 60,000-100,000 related deaths per year. Venous thromboembolism (that collectively defines DVT and/or PE) during hospitalization is the leading cause of disability-adjusted life-years (DALYs) lost in low- and middle-income countries, and the second most common cause in high-income countries, causing loss of more DALYs than nosocomial pneumonia, catheter-related bloodstream infections, and adverse drug events. No identifiable provoking risk factor is reported in about 25%-40% of DVT and pulmonary embolism incidents. Surgery is reported to account for 15% of the cases and especially orthopaedic surgery with postoperative rates of around 1% reported despite pharmacological thromboprophylaxis; immobilization is reported to account for 15% and cancer for about 20% of cases.
Early diagnosis of DVT is crucial and has been proven to prevent life-threatening complications (pulmonary embolism), minimize the risk of long-term disability (post-thrombotic syndrome, recurrent DVT), improve treatment outcomes, and reduce healthcare costs. Despite the progress made in ultrasound imaging and plethysmography techniques, there is a need for new methods to enable continuous monitoring DVT diagnosis in hospitalized and other high-risk patients at the point of care.
ThrombUS+ EU Horizon project brings together an interdisciplinary team of industrial, technology, regulatory, social science and clinical trial experts to develop a novel wearable device for operator free, continuous monitoring in patients with high DVT risk. The devices and software to be developed during this project are expected to achieve automated early DVT detection, provide a continuous assessment of DVT risk and support DVT prevention via extended reality and serious gaming. ThrombUS+ wearable is intended for use by postoperative patients in the ward, during long surgical operations, cancer patients or otherwise bedridden patients at home or in care units, and women during pregnancy and postpartum. ThrombUS+ will use big data sets for artificial intelligence (AI) training collected in the project via 3 large scale clinical studies and will validate the outcome in the clinical setting via 1 early feasibility study and 1 multi-center clinical trial.
This study (ThrombUS_Study_A) aims to collect and create a labelled ultrasound image data set containing ultrasound images series of patients that undergo routine ultrasound scans on lower limbs, because of suspected deep vein thrombosis.
The data will be used to train AI models within ThrombUS+ project to achieve automated detection of deep vein thrombosis on conventional ultrasound scans.
The data set will include negative scans, positive for deep vein thrombosis scans, positive for other diagnosis scans and scans of insufficient quality to aid towards diagnosis, together with imaging metadata and a set of labels for each scan. In addition, the dataset will include pseudonymized patient demographics, referral note, existing known medical conditions at the time of scan, diagnosis based on the scan, operator anonymized ID, and metadata on the ultrasound equipment and scanning protocol parameters.
The data set will be completely anonymized to be used for research purposes, in compliance with the General Data Protection Regulation (GDPR) and the European Health Data Space (EHDS) and the upcoming Artificial Intelligence Act (AIA). Furthermore, the anonymized data set will be described in the Argos/OpenAIRE tool and will be made available through the European Open Science Cloud (EOSC) portal via OpenAIRE, to be used by other researchers for image processing, analysis, and AI model training. This is a non-interventional diagnostic image data collection study.
- Conditions
- Deep Vein Thrombosis
- Keywords
- deep vein thrombosis, ultrasound scan, lower limb, compression ultrasound
- Medical subject headings
- Venous Thrombosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with suspected DVT referred for a DVT ultrasound scan. | Patients with suspected DVT referred for a DVT ultrasound scan will be consecutively selected to account for demographics, medical condition and ultrasound operator diversity in the sample; data selected will be anonymized and included in the data set. In and out-patients referred for an ultrasound scan for suspected DVT will be asked to participate (informed consent process). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ultrasound data
The data set will include negative scans, positive for deep vein thrombosis scans, positive for other diagnosis scans and scans of insufficient quality to aid towards diagnosis, together with imaging metadata and a set of labels for each scan.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2025
- Study start6 Nov 2024
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Deep Vein ThrombosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- ThrombUS+
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Eleni Kaldoudi, Prof., Study director, ATHENA Research Center, GreeceAndrius Macas, Prof. Dr., Principal investigator, Lithuanian University of Health Science [Lietuvos Sveikatos Mokslu Universitetas], LithuaniaMichail Potoupnis, Prof., Principal investigator, School of Medicine, Aristotle University of Thessaloniki and Papageorgiou General Hospital, GreeceElvira Grandone, Prof., Principal investigator, Home Relief of Suffering Hospital [Fondazione Casa Sollievo Della Sofferenza], ItalyMaxime Gautier, Dr., Principal investigator, Simon Veil Hospital, FranceSavvas Defteraios, Prof., Principal investigator, University General Hospital of Alexandroupoli, Greece
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06989255
- Sponsor's protocol ID
- ThrombUS-Study-A
- Other IDs
- 101137227-A
- Acronym
- ThrombUS_A
- Status last verified
- May 2025
- First submitted
- 8 May 2025
- Last updated
- 25 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized ultrasound scan data and anonymized related demographics and diagnosis.
Publications
Kaldoudi, E. et al. (2024). Towards Wearable Continuous Point-of-Care Monitoring for Deep Vein Thrombosis of the Lower Limb. In: Jarm, T., Šmerc, R., Mahnič-Kalamiza, S. (eds) 9th European Medical and Biological Engineering Conference. EMBEC 2024. IFMBE Proceedings, vol 113. Springer, Cham. https://doi.org/10.1007/978-3-031-61628-0_36
ThrombUS+: Wearable Continuous Point-of-Care Monitoring, Risk Estimation and Prevention for Deep Vein Thrombosis, European Union, Horizon Europe Programme, Grant Agreement No, 101137227, 2024-2027, https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/projects-details/43108390/101137227
Maynard G, 2015, Preventing Hospital-Associated Venous Thromboembolism A Guide for Effective Quality Improvement, AHRQ Publication No. 16-0001-EF, https://www.ahrq.gov/sites/default/files/publications/files/vteguide.pdf
Di Nisio M, van Es N, Buller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016 Dec 17;388(10063):3060-3073. doi: 10.1016/S0140-6736(16)30514-1. Epub 2016 Jun 30.
PubMed 27375038Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016 Jan;41(1):3-14. doi: 10.1007/s11239-015-1311-6.
PubMed 26780736ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014 Oct;12(10):1580-90. doi: 10.1111/jth.12698.
PubMed 25302663Nicholson M, Chan N, Bhagirath V, Ginsberg J. Prevention of Venous Thromboembolism in 2020 and Beyond. J Clin Med. 2020 Aug 1;9(8):2467. doi: 10.3390/jcm9082467.
PubMed 32752154Sharif-Kashani B, Behzadnia N, Shahabi P, Sadr M. Screening for deep vein thrombosis in asymptomatic high-risk patients: a comparison between digital photoplethysmography and venous ultrasonography. Angiology. 2009 Jun-Jul;60(3):301-7. doi: 10.1177/0003319708323494. Epub 2008 Oct 14.
PubMed 18854340
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-center Cohort Study for Conventional Ultrasound Image Set Collection to Create a Training Data Set for Research Purposes (Image Processing and Analysis, AI Model Training).
- ClinicalTrials.gov ID
- NCT06989255
- Acronym / sponsor ID
- ThrombUS_A / ThrombUS-Study-A
- Conditions
- Deep Vein Thrombosis
- Keywords
- deep vein thrombosis, ultrasound scan, lower limb, compression ultrasound
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- ThrombUS+University, hospital or other
- Study start
- 6 Nov 2024 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 25 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to collect and create a labelled ultrasound image data set containing ultrasound image series and video clips of patients that undergo routine ultrasound scans on lower limbs, because of suspected deep vein thrombosis.
The data will be used to train an AI model within ThrombUS+ project to achieve automated detection of deep vein thrombosis on conventional ultrasound scans.
Primary objectives:
- Collect and curate imaging data from ultrasound scans of patients suspected for DVT.
- Collect accompanying metadata on patient demographics, referral note, existing known medical conditions at the time of scan, diagnosis based on the scan, operator anonymized ID, metadata on the ultrasound equipment used.
- Anonymize the data set according to established regulations to be used for research purposes and in specific for training an artificial intelligence model to achieve automated DVT detection.
Secondary objectives:
- Describe the data set in the Argos/OpenAIRE tool and make it publicly available through the European Open Science Cloud (EOSC) portal via OpenAIRE, to be used by other researchers for image processing, analysis, and artificial intelligence (AI) model training.
Detailed description
Deep vein thrombosis (DVT) and its fatal complication pulmonary embolism (PE) afflict millions of people worldwide and are responsible for a large percentage of acute hospitalizations. Clinical assessment of DVT is notoriously unreliable because up to 2/3 of DVT episodes are clinically silent and patients are symptom free even when PE has developed. Symptomatic DVT events, that are eventually referred for ultrasound imaging are only the tip of the DVT iceberg. The subgroup of events that evolve to develop clinical indications cannot be accurately predicted and often lead to sudden death from PE regarded as "the leading cause of preventable death in hospitalized patients" and "the number one priority for improving patient safety in hospitals".
Deep vein thrombosis (DVT) is the formation of a blood clot within the deep veins, most commonly those of the lower limbs, causing obstruction of blood flow. In 50% of people with DVT, the clot is at some point detached from the vein wall and travels to the lung to cause pulmonary embolism. About 25% of people experiencing pulmonary embolism (PE) will die from it, making it the 3rd leading cause of cardiovascular death worldwide after stroke and heart attack. Even in patients who do not get PE, recurrent thrombosis and "post-thrombotic syndrome" are major causes of mortality and reduced quality of life.
Recent European population studies report DVT incidence of 70-140 cases/100,000 person-year, which translates to roughly 522,000 to 1.04 million cases per year in Europe. Respectively, Center for Disease Control and Prevention (CDC) reports around 900,000 DVT incidents per year in USA, with an estimate of 60,000-100,000 related deaths per year. Venous thromboembolism (that collectively defines DVT and/or PE) during hospitalization is the leading cause of disability-adjusted life-years (DALYs) lost in low- and middle-income countries, and the second most common cause in high-income countries, causing loss of more DALYs than nosocomial pneumonia, catheter-related bloodstream infections, and adverse drug events. No identifiable provoking risk factor is reported in about 25%-40% of DVT and pulmonary embolism incidents. Surgery is reported to account for 15% of the cases and especially orthopaedic surgery with postoperative rates of around 1% reported despite pharmacological thromboprophylaxis; immobilization is reported to account for 15% and cancer for about 20% of cases.
Early diagnosis of DVT is crucial and has been proven to prevent life-threatening complications (pulmonary embolism), minimize the risk of long-term disability (post-thrombotic syndrome, recurrent DVT), improve treatment outcomes, and reduce healthcare costs. Despite the progress made in ultrasound imaging and plethysmography techniques, there is a need for new methods to enable continuous monitoring DVT diagnosis in hospitalized and other high-risk patients at the point of care.
ThrombUS+ EU Horizon project brings together an interdisciplinary team of industrial, technology, regulatory, social science and clinical trial experts to develop a novel wearable device for operator free, continuous monitoring in patients with high DVT risk. The devices and software to be developed during this project are expected to achieve automated early DVT detection, provide a continuous assessment of DVT risk and support DVT prevention via extended reality and serious gaming. ThrombUS+ wearable is intended for use by postoperative patients in the ward, during long surgical operations, cancer patients or otherwise bedridden patients at home or in care units, and women during pregnancy and postpartum. ThrombUS+ will use big data sets for artificial intelligence (AI) training collected in the project via 3 large scale clinical studies and will validate the outcome in the clinical setting via 1 early feasibility study and 1 multi-center clinical trial.
This study (ThrombUS_Study_A) aims to collect and create a labelled ultrasound image data set containing ultrasound images series of patients that undergo routine ultrasound scans on lower limbs, because of suspected deep vein thrombosis.
The data will be used to train AI models within ThrombUS+ project to achieve automated detection of deep vein thrombosis on conventional ultrasound scans.
The data set will include negative scans, positive for deep vein thrombosis scans, positive for other diagnosis scans and scans of insufficient quality to aid towards diagnosis, together with imaging metadata and a set of labels for each scan. In addition, the dataset will include pseudonymized patient demographics, referral note, existing known medical conditions at the time of scan, diagnosis based on the scan, operator anonymized ID, and metadata on the ultrasound equipment and scanning protocol parameters.
The data set will be completely anonymized to be used for research purposes, in compliance with the General Data Protection Regulation (GDPR) and the European Health Data Space (EHDS) and the upcoming Artificial Intelligence Act (AIA). Furthermore, the anonymized data set will be described in the Argos/OpenAIRE tool and will be made available through the European Open Science Cloud (EOSC) portal via OpenAIRE, to be used by other researchers for image processing, analysis, and AI model training. This is a non-interventional diagnostic image data collection study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with suspected DVT referred for a DVT ultrasound scan. | – | –Patients with suspected DVT referred for a DVT ultrasound scan will be consecutively selected to account for demographics, medical condition and ultrasound operator diversity in the sample; data selected will be anonymized and included in the data set. In and out-patients referred for an ultrasound scan for suspected DVT will be asked to participate (informed consent process). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with suspected DVT referred for a DVT ultrasound scan will be consecutively selected to account for demographics, medical condition and ultrasound operator diversity in the sample; data selected will be anonymized and included in the data set. In and out-patients referred for an ultrasound scan for suspected DVT will be asked to participate (informed consent process).
Key inclusion criteria (3 listed)
- Age ≥18 years.
- The participant has the capacity to consent, and consent is obtained prior to any study-specific procedures.
- The conventional diagnostic DVT algorithm indicates that an ultrasound is needed, or the patient has been referred for a scan on suspicion of DVT.
Key exclusion criteria (3 listed)
- Patients with a known condition or reason that may potentially result in interrupting or stopping the ultrasound examination before its completion.
- Patients considered by their treating physician or the ultrasound operator as non-suitable for a standard ultrasound scan.
- Patients who have not signed the informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Ultrasound data
Time frame: Day 1
The data set will include negative scans, positive for deep vein thrombosis scans, positive for other diagnosis scans and scans of insufficient quality to aid towards diagnosis, together with imaging metadata and a set of labels for each scan.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2025.
- BackgroundKaldoudi, E. et al. (2024). Towards Wearable Continuous Point-of-Care Monitoring for Deep Vein Thrombosis of the Lower Limb. In: Jarm, T., Šmerc, R., Mahnič-Kalamiza, S. (eds) 9th European Medical and Biological Engineering Conference. EMBEC 2024. IFMBE Proceedings, vol 113. Springer, Cham. https://doi.org/10.1007/978-3-031-61628-0_36
- BackgroundThrombUS+: Wearable Continuous Point-of-Care Monitoring, Risk Estimation and Prevention for Deep Vein Thrombosis, European Union, Horizon Europe Programme, Grant Agreement No, 101137227, 2024-2027, https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/projects-details/43108390/101137227
- BackgroundMaynard G, 2015, Preventing Hospital-Associated Venous Thromboembolism A Guide for Effective Quality Improvement, AHRQ Publication No. 16-0001-EF, https://www.ahrq.gov/sites/default/files/publications/files/vteguide.pdf
- Background: PubMed 27375038Di Nisio M, van Es N, Buller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016 Dec 17;388(10063):3060-3073. doi: 10.1016/S0140-6736(16)30514-1. Epub 2016 Jun 30.
- Background: PubMed 26780736Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016 Jan;41(1):3-14. doi: 10.1007/s11239-015-1311-6.
- Background: PubMed 25302663ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014 Oct;12(10):1580-90. doi: 10.1111/jth.12698.
- Background: PubMed 32752154Nicholson M, Chan N, Bhagirath V, Ginsberg J. Prevention of Venous Thromboembolism in 2020 and Beyond. J Clin Med. 2020 Aug 1;9(8):2467. doi: 10.3390/jcm9082467.
- Background: PubMed 18854340Sharif-Kashani B, Behzadnia N, Shahabi P, Sadr M. Screening for deep vein thrombosis in asymptomatic high-risk patients: a comparison between digital photoplethysmography and venous ultrasonography. Angiology. 2009 Jun-Jul;60(3):301-7. doi: 10.1177/0003319708323494. Epub 2008 Oct 14.
- Data management planLink provided by the sponsor.
- ThrombUS+ EU funded project websiteLink provided by the sponsor.
- ThrombUS+ public repository at ZENODOLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized ultrasound scan data and anonymized related demographics and diagnosis.
Related trials for Deep Vein Thrombosis
Recruiting
The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study
Venous Thromboses, Venous Disease
Enrolling by invitationObservational study
ClotTriever® Thrombectomy System Use-Result Survey in Japan
Deep Vein Thrombosis
RecruitingPhase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Symptomatic Venous Thromboembolism (VTE)
RecruitingPhase 3
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Venous Thromboembolism (VTE)
Not yet recruiting
SAFELY RULING OUT DEEP VEIN THROMBOSIS IN PREGNANCY WITH THE LEFt SCORE AND TRIMESTER-ADJUSTED D-DIMER CUTOFFS (the PREG-DVT Study): A PROSPECTIVE COHORT STUDY.
Pregnancy Related, Deep Vein Thrombosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Eleni Kaldoudi, Prof. study director
ATHENA Research Center, Greece
Andrius Macas, Prof. Dr. principal investigator
Lithuanian University of Health Science [Lietuvos Sveikatos Mokslu Universitetas], Lithuania
Michail Potoupnis, Prof. principal investigator
School of Medicine, Aristotle University of Thessaloniki and Papageorgiou General Hospital, Greece
5 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Deep Vein Thrombosis, run by ThrombUS+ at 5 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Greece, France, Italy, Lithuania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eleni Kaldoudi, Prof. (+306937124358, kaldoudi@athenarc.gr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ultrasound data (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06989255, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2025.